18 mei 2020: van onderstaande studie zijn geen updates tot zover. Wel kwam ik op een studie die een overzicht geeft van hoe vaccins werken en in welke combinaties de beste resultaten worden bereikt.

Turning the corner on therapeutic cancer vaccines

Het is teveel om uit deze reviewstudie te citeren en beter om zelf de studie te bekijken. Klik op de titel hierboven. Of bekijk de 166 referenties onderaan dit artikel..

Onderaan artikel staat het abstract van deze reviewstudie met referentielijst. 

4 december 2017: klik op de titel:

Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen



We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune response to MUC1 tumor antigen, we have tested the efficacy of tumor irradiation combined with an MVA-MUC1-IL2 cancer vaccine (Transgene TG4010) for murine renal adenocarcinoma (Renca) cells transfected with MUC1.


Established subcutaneous Renca-MUC1 tumors were treated with 8 Gy radiation on day 11 and peritumoral injections of MVA-MUC1-IL2 vector on day 12 and 17, or using a reverse sequence of vaccine followed by radiation. Growth delays were monitored by tumor measurements and histological responses were evaluated by immunohistochemistry. Specific immunity was assessed by challenge with Renca-MUC1 cells. Generation of tumor-specific T cells was detected by IFN-γ production from splenocytes stimulated in vitro with tumor lysates using ELISPOT assays.


Tumor growth delays observed by tumor irradiation combined with MVA-MUC1-IL-2 vaccine were significantly more prolonged than those observed by vaccine, radiation, or radiation with MVA empty vector. The sequence of cancer vaccine followed by radiation two days later resulted in 55–58% complete responders and 60% mouse long-term survival. This sequence was more effective than that of radiation followed by vaccine leading to 24–30% complete responders and 30% mouse survival. Responding mice were immune to challenge with Renca-MUC1 cells, indicating the induction of specific tumor immunity. Histology studies of regressing tumors at 1 week after therapy, revealed extensive tumor destruction and a heavy infiltration of CD45+ leukocytes including F4/80+ macrophages, CD8+ cytotoxic T cells and CD4+ helper T cells. The generation of tumor-specific T cells by combined therapy was confirmed by IFN-γ secretion in tumor-stimulated splenocytes. An abscopal effect was measured by rejection of an untreated tumor on the contralateral flank to the tumor treated with radiation and vaccine.


These findings suggest that cancer vaccine given prior to local tumor irradiation augments an immune response targeted at tumor antigens that results in specific anti-tumor immunity. These findings support further exploration of the combination of radiotherapy with cancer vaccines for the treatment of cancer.

Exploration of interactions between the immune system and cancer has elucidated the adaptations that enable cancer cells to suppress and evade immune attack. This has led to breakthroughs in the development of new drugs, and, subsequently, to opportunities to combine these with cancer vaccines and dramatically increase patient responses. Here we review this recent progress, highlighting key steps that are bringing the promise of therapeutic cancer vaccines within reach.

Turning the corner on therapeutic cancer vaccines


Recent advances in several areas are rekindling interest and enabling progress in the development of therapeutic cancer vaccines. These advances have been made in target selection, vaccine technology, and methods for reversing the immunosuppressive mechanisms exploited by cancers. Studies testing different tumor antigens have revealed target properties that yield high tumor versus normal cell specificity and adequate immunogenicity to affect clinical efficacy. A few tumor-associated antigens, normal host proteins that are abnormally expressed in cancer cells, have been demonstrated to serve as good targets for immunotherapies, although many do not possess the needed specificity or immunogenicity. Neoantigens, which arise from mutated proteins in cancer cells, are truly cancer-specific and can be highly immunogenic, though the vast majority are unique to each patient’s cancer and thus require development of personalized therapies. Lessons from previous cancer vaccine expeditions are teaching us the type and magnitude of immune responses needed, as well as vaccine technologies that can achieve these responses. For example, we are learning which vaccine approaches elicit the potent, balanced, and durable CD4 plus CD8 T cell expansion necessary for clinical efficacy. Exploration of interactions between the immune system and cancer has elucidated the adaptations that enable cancer cells to suppress and evade immune attack. This has led to breakthroughs in the development of new drugs, and, subsequently, to opportunities to combine these with cancer vaccines and dramatically increase patient responses. Here we review this recent progress, highlighting key steps that are bringing the promise of therapeutic cancer vaccines within reach.


  1. 1.

    Kim, B. K., Han, K. H. & Ahn, S. H. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 81, 41–49 (2011).

  2. 2.

    Roden, R. B. S. & Stern, P. L. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer 18, 240–254 (2018).

  3. 3.

    Kovaiou, R. D., Herndler-Brandstetter, D. & Grubeck-Loebenstein, B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev. Mol. Med. 9, 1–17 (2007).

  4. 4.

    Hurez, V., Padrón, Á., Svatek, R. S. & Curiel, T. J. Considerations for successful cancer immunotherapy in aged hosts. Exp. Gerontol. 107, 27–36 (2018).

  5. 5.

    Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008).

  6. 6.

    Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547–562 (2018).

  7. 7.

    Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

  8. 8.

    Kim, T. K., Herbst, R. S. & Chen, L. Defining and understanding adaptive resistance in cancer immunotherapy. Trends Immunol. 39, 624–631 (2018).

  9. 9.

    Restifo, N. P., Smyth, M. J. & Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16, 121–126 (2016).

  10. 10.

    De Smet, C. et al. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 39, 121–129 (1994).

  11. 11.

    Gnjatic, S. et al. Seromic profiling of ovarian and pancreatic cancer. Proc. Natl Acad. Sci. USA 107, 5088–5093 (2010).

  12. 12.

    Hofmann, O. et al. Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA 105, 20422–20427 (2008).

  13. 13.

    Simpson, A. J. et al. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615–622 (2005).

  14. 14.

    Karbach, J. et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 17, 861–870 (2011).

  15. 15.

    Bakker, A. B. et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005–1009 (1994).

  16. 16.

    Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91, 6458–6462 (1994).

  17. 17.

    Parkhurst, M. R. et al. Identification of a shared HLA-A*0201-restricted T cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895–4901 (1998).

  18. 18.

    Correale, P. et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl Cancer Inst. 89, 293–300 (1997).

  19. 19.

    Lam, K. W. et al. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 15, 13–21 (1989).

  20. 20.

    Vonderheide, R. H., Hahn, W. C., Schultze, J. L. & Nadler, L. M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673–679 (1999).

  21. 21.

    Disis, M. L. et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27, 4685–4692 (2009).

  22. 22.

    Chang, K. & Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl Acad. Sci. USA 93, 136–140 (1996).

  23. 23.

    Finn, O. J. et al. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol. Res. 50, 261–268 (2011).

  24. 24.

    Pedersen, S. R., Sørensen, M. R., Buus, S., Christensen, J. P. & Thomsen, A. R. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J. Immunol. 917, 3955–3967 (2013).

  25. 25.

    Overwijk, W. J. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr. Opin. Immunol. 47, 103–109 (2017).

  26. 26.

    Miller, J. D. et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710–722 (2008).

  27. 27.

    Gulley, J. L. et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59, 663–674 (2010).

  28. 28.

    Bavarian-Nordic website. http://www.bavarian-nordic.com/pipeline/PROSTVAC.aspx.

  29. 29.

    Parkhurst, M. R., Yang, J. C. & Langan, R. C. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).

  30. 30.

    de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607–615 (2012).

  31. 31.

    Lee, C. M. et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 86, 1143–1150 (1999).

  32. 32.

    Chang, M. H., You, S. L. & Chen, C. J., Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101, 1348–1355 (2009).

  33. 33.

    Paavonen, J., Naud, P., Salmerón, J., Wheeler, C. M. & Chow, S. N. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301–314 (2009).

  34. 34.

    de Vos van Steenwijk, P. J. et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol. Immunother. 63, 147–160 (2014).

  35. 35.

    Ault, K. A., for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369, 1861–1868 (2007).

  36. 36.

    Wang, J. W., Hung, C. F., Huh, W. K., Trimble, C. L. & Roden, R. B. Immunoprevention of human papilloma virus associated malignancies. Cancer Prev. Res. 8, 95–104 (2014).

  37. 37.

    Schiller, J. T. & Lowy, D. R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 10, 681–692 (2012).

  38. 38.

    Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078–2088 (2015).

  39. 39.

    Alvarez, R. D. et al. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol. Oncol. 140, 245–252 (2016).

  40. 40.

    Kim, T. J. et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat. Commun. 5, 5317–5323 (2014).

  41. 41.

    Prehn, R. T. & Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769–778 (1957).

  42. 42.

    Kripke, M. L. & Fisher, M. S. Immunologic parameters of ultraviolet carcinogenesis. J. Natl Cancer Inst. 57, 211–217 (1976).

  43. 43.

    Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

  44. 44.

    Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

  45. 45.

    Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).

  46. 46.

    Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).

  47. 47.

    Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).

  48. 48.

    Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257–265 (2015).

  49. 49.

    Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).

  50. 50.

    van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442 (2013).

  51. 51.

    Brown, S. D. et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24, 743–750 (2014).

  52. 52.

    Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).

  53. 53.

    McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).

  54. 54.

    Prickett, T. D. et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4, 669–678 (2016).

  55. 55.

    Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).

  56. 56.

    Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747–752 (2013).

  57. 57.

    Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).

  58. 58.

    Tran, E. et al. T cell transfer therapy targeting mutated KRAS in cancer. N. Engl. J. Med. 375, 2255–2262 (2016).

  59. 59.

    Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).

  60. 60.

    Stevanović, S. et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356, 200–205 (2017).

  61. 61.

    Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).

  62. 62.

    Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324–327 (2014).

  63. 63.

    Wang, Q. J. et al. Identification of T cell receptors targeting KRAS-mutated human tumors. Cancer Immunol. Res. 4, 204–214 (2016).

  64. 64.

    Chheda, Z. S. et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J. Exp. Med. 215, 141–157 (2018).

  65. 65.

    Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091 (2012).

  66. 66.

    Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).

  67. 67.

    Martin, S. D. et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS ONE 11, e0155189 (2016).

  68. 68.

    Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).

  69. 69.

    Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).

  70. 70.

    Santos, P. M. & Butterfield, L. H. Dendritic cell-based cancer vaccines. J. Immunol. 200, 443–449 (2018).

  71. 71.

    Kumai, T., Fan, A., Harabuchi, Y. & Celis, E. Cancer immunotherapy: moving forward with peptide T cell vaccines. Curr. Opin. Immunol. 47, 57–63 (2017).

  72. 72.

    van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T. & Melief, C. J. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 16, 219–233 (2016).

  73. 73.

    Lee, S. H., Danishmalik, S. N. & Sin, J. I. DNA vaccines, electroporation and their applications in cancer treatment. Hum. Vaccin. Immunother. 11, 1889–1900 (2015).

  74. 74.

    Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).

  75. 75.

    Le, D. T., Pardoll, D. M. & Jaffee, E. M. Cellular vaccine approaches. Cancer J. 16, 304–310 (2010).

  76. 76.

    Hege, K. M., Jooss, K. & Pardoll, D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int. Rev. Immunol. 25, 321–352 (2006).

  77. 77.

    Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).

  78. 78.

    Armstrong, C. A. et al. Antitumor effects of granulocyte–macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56, 2191–2198 (1996).

  79. 79.

    Sanda, M. G. et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151, 622–628 (1994).

  80. 80.

    Dunussi-Joannopoulos, K. et al. Gene immunotherapy in murine acute myeloid leukemia: granulocyte–macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 91, 222–230 (1998).

  81. 81.

    Small, E. J. et al. Granulocyte macrophage colony-stimulating factor—secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13, 3883–3891 (2007).

  82. 82.

    Lipson, E. J. et al. Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J. Transl. Med. 13, 214–221 (2015).

  83. 83.

    Laheru, D. et al. Allogeneic granulocyte macrophage colony-stimulating factor secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14, 1455–1463 (2008).

  84. 84.

    Salgia, R. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophagecolony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 4, 624–630 (2003).

  85. 85.

    Higano, C. et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, LBA150 (2009).

  86. 86.

    Small, E. et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, a07 (2009).

  87. 87.

    Santos, P. M. & Butterfield, L. H. Dendritic cell-based cancer vaccines. J. Immunol. 200, 443–449 (2018).

  88. 88.

    Kantoff, P. W. et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

  89. 89.

    Butterfield, L. H. et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J. Immunother. 31, 294–309 (2008).

  90. 90.

    Ribas, A. et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. 27, 354–367 (2004).

  91. 91.

    Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 262, 3–11 (1991).

  92. 92.

    Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat. Rev. Urol. 11, 153–162 (2014).

  93. 93.

    Saltzman, D. A. Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells. Expert Opin. Biol. Ther. 5, 443–449 (2005).

  94. 94.

    Bermudez-Humaran, L. G. et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol. 175, 7297–7302 (2005).

  95. 95.

    Toussaint, B., Chauchet, X., Wang, Y., Polack, B. & Le Gouëllec, A. Live-attenuated bacteria as a cancer vaccine vector. Expert Rev. Vaccin. 12, 1139–1154 (2013).

  96. 96.

    Wood, L. M. & Paterson, Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front. Cell. Infect. Microbiol. 4, 51–60 (2014).

  97. 97.

    Bolhassani, A., Naderi, N. & Soleymani, S. Prospects and progress of Listeria-based cancer vaccines. Expert Opin. Biol. Ther. 17, 1389–1400 (2017).

  98. 98.

    Le, D. T. et al. Safety and survival With GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Clin. Oncol. 33, 1325–1333 (2015).

  99. 99.

    Le, D. T. et al. Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). 2017 Gastrointestinal Cancers Symposium. J. Clin. Oncol. 35, 345–355 (2017).

  100. 100.

    Aduro press release. http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2322291.

  101. 101.

    Cecco, S. et al. Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Curr. Cancer Drug Targets 11, 85–102 (2011).

  102. 102.

    Lesterhuis, W. J., Haanen, J. B. & Punt, C. J. Cancer immunotherapy—revisited. Nat. Rev. Drug Discov. 10, 591–600 (2011).

  103. 103.

    Bijker, M. S. et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC focused antigen presentation. Eur. J. Immunol. 38, 1033–1042 (2008).

  104. 104.

    Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. & Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T cell tolerance induction. Proc. Natl Acad. Sci. USA 93, 7855–7860 (1996).

  105. 105.

    Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M. & Melief, C. J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911–3918 (1996).

  106. 106.

    Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465–472 (2013).

  107. 107.

    Cho, H. I. & Celis, E. Optimized peptide vaccines eliciting extensive CD8 T cell responses with therapeutic antitumor effects. Cancer Res. 69, 9012–9020 (2009).

  108. 108.

    Cho, H. I., Barrios, K., Lee, Y. R., Linowski, A. K. & Celis, E. BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T cell responses. Cancer Immunol. Immunother. 62, 787–799 (2013).

  109. 109.

    Zom, G. G., Khan, S., Filippov, D. V. & Ossendorp, F. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv. Immunol. 114, 177–201 (2012).

  110. 110.

    Wen, Y. & Collier, J. H. Supramolecular peptide vaccines: tuning adaptive immunity. Curr. Opin. Immunol. 35, 73–79 (2015).

  111. 111.

    Sultan, H. et al. Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol., Immunother. 66, 203–213 (2017).

  112. 112.

    Overwijk, W. W. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr. Opin. Immunol. 47, 103–109 (2017).

  113. 113.

    Zhu, X. et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med. 5, 10–17 (2007).

  114. 114.

    van Duikeren, S. et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J. Immunol. 189, 3397–3403 (2012).

  115. 115.

    Zhang, H. et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. J. Biol. Chem. 284, 9184–9191 (2009).

  116. 116.

    Janssen, E. M. et al. CD4+ T cell help helps control CD8+ T cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88–93 (2010).

  117. 117.

    Rosalia, R. A. et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T cell activation. Eur. J. Immunol. 43, 2554–2565 (2013).

  118. 118.

    Larocca, C. & Schlom, J. Viral vector-based cancer vaccines. Cancer J. 17, 359–371 (2011).

  119. 119.

    DiPaola, R. S. et al. A phase I trial of pox PSA vaccines (PROSTVAC -VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl. Med. 4, 1–5 (2006).

  120. 120.

    Kantoff, P. W., Gulley, J. L. & Pico-Navarro, C. Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 35, 124–125 (2017).

  121. 121.

    Arlen, P. M. et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178, 1515–1520 (2007).

  122. 122.

    Cho, H. et al. Vaccine based immunotherapy regimen (VBIR) for the treatment of prostate cancer. Cancer Res76 (14 Supplement), LB-093-LB-093 (2016).

  123. 123.

    Jorritsma, S. H. T., Gowans, E. J., Grubor-Bauk, B. & Wijesundara, D. K. Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine 34, 5488–5494 (2016).

  124. 124.

    Sardesai, N. Y. & Weiner, D. B. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23, 421–429 (2011).

  125. 125.

    Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078–2088 (2015).

  126. 126.

    Diken, M., Kranz, L. M., Kreiter, S. & Sahin, U. mRNA: A versatile molecule for cancer vaccines. Curr. Issues Mol. Biol. 22, 113–128 (2017).

  127. 127.

    Karikó, K. & Weissman, D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr. Opin. Drug Discov. Devel. 10, 523–532 (2007).

  128. 128.

    Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).

  129. 129.

    Lundstrom, K. & Replicon, R. N. A. viral vectors as vaccines. Vaccines 4, 39 (2016).

  130. 130.

    Lu, D., Benjamin, R., Kim, M., Conry, R. M. & Curiel, D. T. Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther. 1, 245–252 (1994).

  131. 131.

    Wasungu, L. & Hoekstra, D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 116, 255–264 (2006).

  132. 132.

    Little, S. R. et al. Poly-β amino ester containing microparticles enhance the activity of nonviral genetic vaccines. Proc. Natl Acad. Sci. USA 101, 9534–99539 (2004).

  133. 133.

    Phua, K. K. L., Leong, K. W. & Nair, S. K. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J. Control. Release 166, 227–233 (2013).

  134. 134.

    Su, X., Fricke, J., Kavanagh, D. G. & Irvine, D. J. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm. 8, 774–787 (2011).

  135. 135.

    Phua, K. K. L., Nair, S. K. & Leong, K. W. Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale 6, 7715–7729 (2014).

  136. 136.

    Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).

  137. 137.

    Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD- 1 blockade. Sci. Transl. Med. 7, 283ra52 (2015).

  138. 138.

    Ali, O. A., Lewin, S. A., Dranoff, G. & Mooney, D. J. Vaccines combined with immune checkpoint antibodies promote cytotoxic T cell activity and tumor eradication. Cancer Immunol. Res. 4, 95–100 (2016).

  139. 139.

    Massarelli, E. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncolhttps://doi.org/10.1001/jamaoncol.2018.4051 (2018).

  140. 140.

    Romano, E. et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J. Transl. Med. 12, 97–104 (2014).

  141. 141.

    Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

  142. 142.

    Khong, H. & Overwijk, W. W. Adjuvants for peptide-based cancer vaccines. J. Immunother. Cancer 4, 56–67 (2016).

  143. 143.

    Kumai, T., Kobayashi, H., Harabuchi, Y. & Celis, E. Peptide vaccines in cancer-old concept revisited. Curr. Opin. Immunol. 45, 1–7 (2017).

  144. 144.

    Moran, A. E., Kovacsovics-Bankowski, M. & Weinberg, A. D. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25, 230–237 (2013).

  145. 145.

    Murata, S. et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol. 176, 974–983 (2006).

  146. 146.

    De Smedt, T. et al. OX40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168, 661–670 (2002).

  147. 147.

    Sorensen, M. R., Holst, P. J., Steffensen, M. A., Christensen, J. P. & Thomsen, A. R. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 28, 6757–6764 (2010).

  148. 148.

    Linch, S. N. et al. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice. Proc. Natl Acad. Sci. USA. 113, E319–E327 (2016).

  149. 149.

    Schwartzentruber, D. J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119–2127 (2011).

  150. 150.

    Yang, Y., Shao, Z. & Gao, J. Antitumor Effect of a DNA vaccine harboring prostate cancer-specific antigen with IL-12 as an intramolecular adjuvant. J. Mol. Microbiol. Biotechnol. 27, 168–174 (2017).

  151. 151.

    Anguille, S. et al. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum. Vaccin. Immunother. 9, 1956–1961 (2013).

  152. 152.

    Ferrara, T. A., Hodge, J. W. & Gulley, J. L. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr. Opin. Mol. Ther. 11, 37–42 (2009).

  153. 153.

    Gameiro, S. R. et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T cell killing. Oncotarget 5, 403–416 (2014).

  154. 154.

    Cadena, A. et al. Radiation and anti-cancer vaccines: a winning combination. Vaccines 6, 9 (2018).

  155. 155.

    Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 14, 690–714 (2015).

  156. 156.

    Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N. Eng. J. Med. 378, 2078–2092 (2018).

  157. 157.

    Gatti-Mays, M. E. et al. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum. Vaccin. Immunother13, 2561–2574 (2017).

  158. 158.

    Welters, M. J. et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci. Transl. Med. 8, 334ra52 (2016).

  159. 159.

    Quoix, E. et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 17, 212–223 (2016).

  160. 160.

    Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P. & van Lier, R. A. W. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat. Immunol. 19, 538–546 (2018).

  161. 161.

    Blanc, C. et al. Targeting resident memory T cells for cancer immunotherapy. Front Immunol. 9, 1722 (2018).

  162. 162.

    Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181–273 (2000).

  163. 163.

    Garrido, F., Cabrera, T. & Aptsiauri, N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 127, 249–256 (2010).

  164. 164.

    Mimura, K. et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J. Immunol. 191, 6261–6272 (2013).

  165. 165.

    Pollack, B. P., Sapkota, B. & Cartee, T. V. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin. Cancer Res. 17, 4400–4413 (2011).

  166. 166.

    Srivastava, R. M. et al. STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients. Cancer. Immunol. Res. 3, 936–945 (2015).

Plaats een reactie ...

Reageer op "Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen"

Gerelateerde artikelen

Gerelateerde artikelen

CYAD-101, een vorm van CAR-T >> Een petscan met Novel 18F-Labeled >> Radiotherapy and MVA-MUC1-IL-2 >> Chronische Lymfatische Leukemie: >> S-1 plus oxaliplatine samen >> CRISPR-Cas9 gentherapie gericht >> Lenvatinib Plus Pembrolizumab >> Het voordeel van immunotherapeutische >> Melanomen: Er is een sterk >> CAR-T cel therapie is een >>